Analyst Report: Upgrade for access Securisyn’s Tech Saves Patients’ Lives and Hospitals’ Bottom Lines

Archaic Technology

Note: This recommendation was co-authored by KingsCrowd Investment Research Analyst Teddy Lyons.

I prefer to stay as far away from hospitals as possible. 

Don’t get me wrong. I appreciate hospitals. But I also know that hospitals are businesses that are concerned with revenue and profit just like any other company. And that means that patient care is not always a top priority. This is America. We live in a capitalist, for-profit society. So I get it. But for some reason, knowing this about hospitals rubs me the wrong way.

I do give hospitals credit for having the most cutting-edge tools at their disposal, which is some consolation. That’s certainly true for imaging and surgical technology. 

But what if I told you that there is an area of patient care where practitioners use tape as the main source of stabilization? Can’t be, right?

Well, that is precisely the case when it comes to the stabilization of breathing tubes used to keep ventilated patients alive. Tape! Let that sink in. Because it’s as bad as it sounds. Tape is so unstable that unplanned extubation (the accidental removal of a breathing tube from an airway) is associated with 33,000 preventable deaths each year in the United States. 

The technology is archaic. In fact, it’s a joke. Somehow, no company has stepped forward to offer a product that can prevent the epidemic of endotracheal tube slippage and unplanned extubation. 

Until now.

The company I’m introducing to you today — Securisyn Medical — has patented a tube stabilization device that solves the life-threatening issues surrounding unplanned extubation and tube slippage. 

For hospitals, this is huge. Any opportunity to lower fatality rates is an obvious reason to purchase a product like SolidAIRity Flex, Securisyn’s flagship breathing stabilization product. 

And because the product never enters the body, Securisyn’s products do not need FDA approval. That’s a big investing risk off the table. 

Pay Annually

Monthly Annually

and save 17%

This article requires: Edge Pro

Full site access including KingsCrowd's qualitative analyst reports.

$

49.95 /month

41.58 /annually

 

What's included

• Everything in Edge, plus
• Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
• Search and filter based on Analyst Reports
• In-depth risk ratings for every raise

• Startup Portfolio Tracking
• Follows
• Company Search Table
• Founder Profiles
• Trending Companies
• Fundraising Analytics
• News and Crowdopedia

Company Search table full access, except for Analyst Reports.

Charts and trends of capital raised by platform, security type, industry, and more.

Unlimited Top Deal, Deal to Watch, Neutral, and Underweight reports.

Unlock "Analyst Report" filters in the Company Search table.